Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Daromun + Onfekafusp alfa |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Daromun | L19-IL2/L19-TNF-alpha|Darleukin/Fibromun|L19IL2/L19TNF | Daromun consists of a mixture of darleukin, a recombinant IL2 linked to the fibronectin extra domain B (EDB) targeting single-chain variable fragment (L19), and fibromun, a human TNF-alpha linked to L19, which binds to cells expressing fibronectin EDB in tumor neovasculature, potentially resulting in the induction of antitumor immune response against tumor cells expressing EDB-containing fibronectin (NCI Drug Dictionary). | ||
| Onfekafusp alfa | Fibromun|L19-TNF-alpha|L19TNF | Onfekafusp alfa comprises TNFalpha linked to a single chain variable fragment targeting fibronectin extra-domain B, which may increase antitumor immune response (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02938299 | Phase III | Daromun + Onfekafusp alfa | Neoadjuvant L19IL2/L19TNF- Pivotal Study (Pivotal) | Active, not recruiting | POL | ITA | FRA | DEU | 0 |